HMO Composition for Infant Language Development
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current nutritional compositions aimed at enhancing language development in children lack evidence of effectiveness for human milk oligosaccharides beyond neutral HMOs, and there is a need for a delivery method that is safe, easily accepted, cost-effective, and free from side effects.
Innovation Solution
A nutritional composition comprising 3′ sialyllactose (3-SL), 6′ sialyllactose (6-SL), and 3-fucosyllactose (3-FL) or their combinations, administered through a method involving analysis of a mother's milk for A-tetrasaccharide presence and supplementation with these oligosaccharides to support language development in infants and young children.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If nutritional compositions include only neutral HMOs (like LNnT), then production is simpler and cost is lower, but language development benefits are limited and not well-supported by evidence
Solution Approach 1:
The patent changes the chemical parameters of HMOs from neutral (LNnT) to sialylated (3-SL, 6-SL) and fucosylated (3-FL) variants. This parameter change enables the oligosaccharides to interact with specific receptors (sialic acid receptors, fucose-binding proteins) in the brain, thereby achieving language development benefits while maintaining production feasibility through established HMO synthesis methods
Solution Approach 2:
The patent creates a composite HMO formulation combining multiple types (3-SL, 6-SL, 3-FL) rather than using a single neutral HMO. This composite approach leverages the synergistic effects of different oligosaccharide structures on brain development, gut microbiota modulation, and immune function, thereby achieving superior language development outcomes compared to single-component formulations
2Reliability
If complex HMO formulations (3-SL, 6-SL, 3-FL) are used to improve language development, then effectiveness is enhanced, but manufacturing complexity and cost increase
Solution Approach 1:
The patent segments the complex HMO formulation into three distinct, well-characterized components (3-SL, 6-SL, 3-FL). Each component can be produced separately using established biochemical synthesis methods, then combined in defined ratios. This segmentation simplifies quality control and manufacturing compared to producing a single complex mixture, while maintaining the synergistic benefits of multiple HMO types
3Reliability
If HMOs are administered to support language development, then language skills improve, but there may be side effects or poor acceptance by parents
Solution Approach 1:
The patent uses synthetic or semi-synthetic HMOs that are chemically identical to naturally occurring human milk oligosaccharides. This copying of natural structures ensures compatibility with the infant's digestive system and gut microbiota, eliminating side effects while maintaining the language development benefits observed in breastfed infants. The natural familiarity of these structures to the infant's system also ensures poor rejection or allergic reactions
Solution Approach 2:
The patent utilizes HMOs as intermediary substances that indirectly support language development by modulating gut microbiota composition and producing neuroactive metabolites. Rather than directly stimulating brain development, the HMOs act as mediators that create a favorable gut-brain axis environment, thereby achieving language benefits through a natural, indirect pathway that minimizes side effects and enhances parental acceptance
Data Source
AI summary
The present invention relates to a nutritional composition comprising at least one human milk oligosaccharide comprising 3′ sialyllactose (3-SL), 6′ sialyllactose (6-SL), 3-fucosyllactose and any combination thereof for improving language development in a subject, preferably born from a A-tetrasaccharide positive mother and/or the subject fed with a mother's milk rich in A-tetrasaccharide